Table 2. Vote-counting strategy of abnormal miR-10b expression based on tumor type.
| Subset of studies with fold-change | |||||||
|---|---|---|---|---|---|---|---|
| Direction of expression | Cancer type | No. of studies (reference) | Total sample size | No. of studies | Total sample size | Mean fold-change | Range |
| Up-regulated | HCC | 2 (Shen J, 2012;Li QJ, 2012) | 115 | 1 | 74 | 17.10 | - |
| Esophageal cancer | 2 (Tian YY, 2010;Xie Z, 2013) | 138 | 1 | 58 | 58.70 | - | |
| Oral cancer | 1(Lu YC, 2012) | 97 | 1 | 97 | 4 | - | |
| Breast cancer | 5(Ma L, 2007; Zhao FL, 2012; Teplyuk NM, 2012; Chan M, 2013) | 316 | 1 | 54 | 1.77 | - | |
| Lung cancer | 7 (Teplyuk NM, 2012; Roth C, 2011; Cui EH, 2013; Shen Y, 2013) | 805 | 5 | 735 | 3.64 | 0.77:6.50 | |
| Glioma | 3 (Sasayama T, 2009; Teplyuk NM,2012; Guessous F, 2013) | 108 | 2 | 74 | 33.86 | 0.08:364 | |
| Vestibular schwannomas | 1(Torres-Martin M, 2013) | 10 | 1 | 10 | 269.19 | - | |
| Pituitary adenomas | 2(Liang S, 2013) | 22 | 2 | 22 | 27.24 | 5.74:48.73 | |
| Prostate Cancer | 1(Walter BA,2013) | 50 | 1 | 50 | 13.88 | - | |
| Down-regulated | Renal cancer | 1 (Heneghan HM, 2010) | 83 | 1 | 83 | −1.53 | - |
| Colon cancer | 3 (Heneghan HM, 2010, Pizzini S, 2013) | 194 | 3 | 194 | −1.94 | −1.64: −2.81 | |
| Melanoma | 1 (Heneghan HM, 2010) | 73 | 1 | 73 | −3.13 | - | |
| Breast cancer | 1 (Iorio MV, 2005) | 86 | 1 | 86 | −1.53 | - | |
| HCC | 1 (Zaravinos A, 2012) | 77 | 1 | 77 | −3.13 | - | |
| EEC | 1 (Tsukamoto O, 2014) | 42 | 1 | 42 | −1.27 | - | |
| ccRCC | 2 (Wotschofsky Z, 2012; Wu X,2012) | 95 | 2 | 95 | −2.08 | −1.19: −5.55 | |
Abbreviations: HCC: hepatocellular carcinoma; ccRCC: clear cell renal cell carcinomas; NSCLC: non-small cell lung cancer; EEC: endometrioid endometrial carcinoma.